-

01:51:42 PM

OTIC Stock News

OTIC - Otonomy Inc

12/22/22 7:53 AM

Nasdaq : OTIC

Otonomy Announces Change in Stock Exchange Listing

Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at the open of

RHEA-AI

neutral

12/19/22 4:53 PM

Nasdaq : OTIC

Otonomy Provides Corporate Update

Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution (“Plan of Dissolution”) that would include the distribution of

RHEA-AI

neutral

11/10/22 4:05 PM

Nasdaq : OTIC

earnings

Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the

RHEA-AI

neutral

10/13/22 7:30 AM

Nasdaq : OTIC

Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss

Higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baseline Lack of activity compared to 0.3 mg dose evaluated in prior studies may be due to a complex dose-response relationship that has been observed with neurotrophins Otonomy intends to explore

RHEA-AI

neutral

08/01/22 7:30 AM

Nasdaq : OTIC

clinical trial

Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus

OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepoints Company to discontinue development of OTO-313 and implement other measures to extend its cash runway Clinical focus shifts to OTO-413 following positive Phase 2a

RHEA-AI

neutral

07/25/22 4:05 PM

Nasdaq : OTIC

earnings

Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line results expected in third quarter of 2022 Positive top-line results announced for OTO-413 Phase 2a in

RHEA-AI

neutral

07/18/22 7:30 AM

Nasdaq : OTIC

conferencesearnings

Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update at 4:30 p.m.

RHEA-AI

neutral

05/18/22 7:30 AM

Nasdaq : OTIC

conferences

Otonomy to Participate in the H.C. Wainwright Global Investment Conference

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the H.C. Wainwright Global Investment Conference (Hybrid Conference). A pre-recorded

RHEA-AI

neutral

05/12/22 7:30 AM

Nasdaq : OTIC

Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of preclinical data for OTO-825 at the upcoming American Society of Gene & Cell Therapy

RHEA-AI

neutral

05/09/22 4:04 PM

Nasdaq : OTIC

earnings

Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update

Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluation OTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected in August 2022; clinical safety evaluation of higher and bilateral dosing ongoing OTO-825

RHEA-AI

neutral

1 2 3 4 5 6 7 Next